Alcon Stock - analyst consensus and valuation snapshot
Published on 06/21/2026 at 14:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/21/2026, 14:31 CET. Details in the imprint.
Alcon (CH0432492467) is drawing steady attention from the analyst community as a core name in global eye care. The stock currently reflects a premium valuation against sector averages, while consensus remains tilted toward positive long-term growth expectations according to major data aggregators.
All news and analysis on Alcon stock
Further figures, estimates and disclosures on Alcon are collected on the ad-hoc-news topic page and the company’s Investor Relations site.
What current numbers show
Alcon reports in US dollars but its primary listing trades in Swiss francs on SIX Swiss Exchange. Recent data from MarketScreener shows the stock at around CHF 52.86 at the June 19 close, implying a modest gain over the past five trading days.
The same source shows a price-earnings ratio of roughly 30.4 times based on current year estimates, placing Alcon at a valuation premium to many diversified healthcare names. Net debt remains manageable relative to cash flow, supporting ongoing investment in product innovation.
Analyst ratings and consensus
Analyst houses tracked by major data platforms keep a broadly constructive stance on Alcon. According to consensus summaries, most banks rate the stock as Buy or equivalent, with a smaller group at Hold and very few outright Sells.
Target prices compiled by these services typically indicate upside from current levels, though dispersion between the highest and lowest estimates has widened slightly in recent months. That reflects differing views on the pace of margin expansion and capital allocation priorities.
The product behind the stock
Alcon generates revenue primarily from surgical ophthalmology systems and vision care products. Flagship offerings include advanced intraocular lenses used in cataract surgery and a broad range of contact lenses and eye-care solutions marketed globally to ophthalmologists and consumers.
Where the stock trades today
Alcon shares (CH0432492467) trade on SIX Swiss Exchange at CHF 52.86 as of 06/19/2026, 17:30 CET.
Key facts on Alcon stock
- Company: Alcon Inc.
- ISIN: CH0432492467
- WKN: A2PDXE
- Ticker: ALC
- Venue: SIX Swiss Exchange
- Price (as of 06/19/2026, 17:30 CET): 52.86 CHF
- Market cap: 26,000,000,000 CHF (as of 06/19/2026)
- Sector / Industry: Health Care - Medical Equipment & Supplies
- Index membership: SMI
- Next earnings date: 08/15/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
